FDA to Introduce Bonuses to Slash Drug Approval Times Amid Staffing Shortages

Key Facts

The US Food and Drug Administration (FDA) is launching a new incentive program designed to significantly accelerate the drug approval process. Under the new plan, the agency aims to reduce review times from the current average of 29 months to as little as 6 months. To achieve this, financial bonuses will be offered to staff members to incentivize expedited reviews, addressing a critical 20% reduction in the workforce since the start of the Trump administration. This move toward deregulation is expected to lower R&D overhead and accelerate revenue cycles for pharmaceutical companies by shortening the path to commercialization. Market analysts view this development as a major tailwind for the healthcare and biotech sectors, potentially boosting major instruments such as XLV, IBB, and leading drugmakers.